TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04886154

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MenABCWY-2Gen low dose vaccine
Description: MenABCWY-2Gen low dose vaccine is administered intramuscularly in the deltoid region of the non-dominant arm as 2 doses to participants in the ABCWY low dose Group in study Phase I, ABCWY low dose_06 Group and ABCWY low dose_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY low dose_01 Group, ABCWY low doseS_02 Group and ABCWY low doseS_06 Group in study Phase II (Sourcing).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MenABCWY-2Gen high dose vaccine
Description: MenABCWY-2Gen high dose vaccine is administered intramuscularly in the deltoid region of the non-dominant arm as 2 doses to participants in the ABCWY high dose Group in study Phase I, ABCWY high dose_06 Group and ABCWY high dose_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY high dose_01 Group, ABCWY high doseS_02 Group and ABCWY high doseS_06 Group in study Phase II (Sourcing).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MenABCWY-2Gen high dose vaccine
Description: MenABCWY-2Gen high dose vaccine is administered intramuscularly in the deltoid region of the non-dominant arm as 2 doses to participants in the ABCWY high dose Group in study Phase I, ABCWY high dose_06 Group and ABCWY high dose_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY high dose_01 Group, ABCWY high doseS_02 Group and ABCWY high doseS_06 Group in study Phase II (Sourcing).
Study: NCT06078501

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo buccal administration 2-3 hours prior to procedure
Study: NCT06006338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D Printed Model for preoperative planning
Description: Besides conventional preoperative planning based on contrast-enhanced CT/MRI, the investigator refers to a 3D printed model to determine the optimal surgical approach via a trial-and-error method. Specifically, a personalized 3D printed model is fabricated. By referring to the printed model and CT/MRI images, a preliminary surgical trace is determined. Then, a simulation surgery is performed on the model, and surgical margin and the potential injury of vital vascular structures are evaluated. This assessment leads to the adjustment of the surgical path as necessary. The refined surgical route is then validated through a second simulation surgery performed on the healed 3D model. This iterative process is repeated multiple times, allowing for a comprehensive exploration of various approaches until the optimal surgical strategy crystallizes. Next, the investigator proceeds to execute the real surgery on the participant, meticulously adhering to the determined optimal surgical approach.
Study: NCT03998293

Intervention type: DRUG
Group type: OTHER
Intervention: Somatostatin
Description: infused to block endogenous insulin secretion over a 4 hour period
Study: NCT05511896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repeated trunk flexion
Description: A 60-min intermittent trunk flexion protocol. Participants will sit on a standard height sit, with their knees bent at approximately 90° with their hands crossed on their chest. They will perform 40 sets of 60 s of maintaining a flexed position, interspersed with 30 s of rest. Participants will achieve the flexed position by tilting the pelvis posteriorly and leaning forward. During rest, participants will sit up straight without leaning on the support.
Study: NCT04689997

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cSBI
Description: The standard CRAFFT SU screen has additional questions about reasons to use or not use, SU expectancies of effect and embedded education. The teens of enhanced care PCPs will also complete a Strengths and Goals tool. Data from both will be used by the PCP in counseling regarding continued abstention, reduction or cessation of SU or referral. Teens will also get monthly text messages about goals.
Study: NCT05557188

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Grounding
Description: Each pregnant woman in the placebo group is going to be informed about the grounding stick and how to use it, with a 2-minute video showing. Participants walk on the ground for 30 minutes daily and go on for four weeks. During the program, the pregnant women will be called to their homes every week and necessary reminders will be made.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham grounding
Description: Each pregnant woman in the placebo group is going to be informed about the Sham grounding stick and how to use it, with a 2-minute video showing. Participants walk on the ground for 30 minutes daily and go on for four weeks. During the program, the pregnant women will be called to their homes every week and necessary reminders will be made.
Study: NCT06437964

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No use of prophylactic antibiotics
Description: In the endoscopic secondary prevention of cirrhotic patients with gastroesophageal variceal bleeding, do not use any antibiotics before the endoscopic operation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No use of prophylactic antibiotics
Description: In the endoscopic secondary prevention of cirrhotic patients with gastroesophageal variceal bleeding, do not use any antibiotics before the endoscopic operation.
Study: NCT06002750

Intervention type: OTHER
Intervention: disease
Description: Do you have dermatomyositis
Study: NCT05651750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: receiving 2 months treatment with Montelukast once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate
Description: receiving 2 months treatment with Fluticasone Furoate nasal spray once a day
Study: NCT06277908

Intervention type: PROCEDURE
Intervention: Elective Surgery for gastric cancer
Description: Total, distal or proximal gastrectomy via open, laparoscopic or robotic approach

Intervention type: PROCEDURE
Intervention: Elective Surgery for gastric cancer
Description: Total, distal or proximal gastrectomy via open, laparoscopic or robotic approach
Study: NCT06029725

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency microneedling combined with 1927 nm thulium laser
Description: 1. session: radiofrequency microneedling + 1927 nm thulium laser~2. session: 1927 nm thulium laser monotherapy~3. session: 1927 nm thulium laser monotherapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency microneedling monotherapy
Description: 1 session: radiofrequency microneedling monotherapy
Study: NCT04692818

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: GE Logiq E10 clinical ultrasound scanner
Description: 2D B-mode, Doppler, and shear wave elastography images of the lesion

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Verasonics research scanner
Description: 3D B-mode imaging, microvessel imaging, and shear wave elastography
Study: NCT06679803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Chats after Stroke (PA-ChatS)
Description: PA-ChatS consists of (1) self-monitoring step count using a Fitbit Inspire, and (2) behavioral activation for stepping activity delivered via the telephone and guided by the PA-ChatS workbook.~Participants will receive education regarding the physical activity after stroke, American Heart/Stroke Association guidelines for post-stroke physical activity levels, and an overview of the intervention activities. They will then use the Fitbit data to monitor average daily step counts, set a new step count goals (increasing by 5 to 10% of the daily average step count from the prior week), and create a specific plan for achieving the new step count goal. The interventionist will collaboratively problem solve with the participant to identify strategies to overcome barriers to stepping activity and maintain safety.
Study: NCT05862818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Day shift protocol - Diet order A-B
Description: Research participants will be assigned to day shift condition and Diet A-B order condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Day shift protocol - Diet order A-B
Description: Research participants will be assigned to day shift condition and Diet A-B order condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Day shift protocol - Diet order B-A
Description: Research participants will be assigned to day shift condition and Diet B-A order condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Day shift protocol - Diet order B-A
Description: Research participants will be assigned to day shift condition and Diet B-A order condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Night shift protocol - Diet order A-B
Description: Research participants will be assigned to simulated night shift condition and Diet A-B order condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Night shift protocol - Diet order A-B
Description: Research participants will be assigned to simulated night shift condition and Diet A-B order condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Night shift protocol - Diet order B-A
Description: Research participants will be assigned to simulated night shift condition and Diet B-A order condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Night shift protocol - Diet order B-A
Description: Research participants will be assigned to simulated night shift condition and Diet B-A order condition.
Study: NCT06735404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid care
Description: The hybrid care model will consist of a combination of digital tools and/or task shifting of certain healthcare providers. Examples are:~* Telemonitoring: patients perform self-measurements through e.g. sensors, wearables, or (mobile) applications to get insight in their health status (supporting self-management) and report this to their healthcare provider(s), when relevant~* Teleconsultation: patients communicate with their healthcare provider(s) remotely~* Personal health portals and self-management applications~* Online prescription requests: patients request prescription online
Study: NCT06734702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Description: The neoadjuvant regimen prior to radiotherapy consists of albumin-bound paclitaxel 260 mg/m², cisplatin 75 mg/m², and tislelizumab 200 mg, administered every 3 weeks for 2 cycles.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent chemoradiotherapy
Description: Definitive dose of thoracic radiotherapy with concurrent chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy
Description: Definitive dose of thoracic radiotherapy with concurrent chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Consolidative immunotherapy
Description: Following the completion of chemoradiotherapy, Tislelizumab consolidation therapy will be administered based on treatment efficacy and the patient's physical condition, for a total duration of 1 year, starting 1-2 months after chemoradiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidative immunotherapy
Description: Following the completion of chemoradiotherapy, Tislelizumab consolidation therapy will be administered based on treatment efficacy and the patient's physical condition, for a total duration of 1 year, starting 1-2 months after chemoradiotherapy.
Study: NCT06735456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mandala
Description: The patient will undergo mandala painting during 1 session of chemotherapy.
Study: NCT06734598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Echo-guided Botox injection
Description: Echo-guided Botox injection to the masticatory muscles

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: echo-guided normal saline injection
Description: echo-guided normal saline injection
Study: NCT06734572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FAPIBiotin
Description: The dose will be 148-296 MBq given intravenously.
Study: NCT06734377

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delta TMS
Description: TMS will be administered at the frequency of delta oscillation (2.2Hz)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delta TMS
Description: TMS will be administered at the frequency of delta oscillation (2.2Hz)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta TMS
Description: TMS will be administered at the frequency of theta oscillation (6.5Hz)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta TMS
Description: TMS will be administered at the frequency of theta oscillation (6.5Hz)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arrhythmic TMS
Description: TMS will be administered arrhythmically. In this intervention, the inter-pulse intervals are randomized between delta and theta durations for each trial, ensuring the same total number of pulses but without rhythmic consistency

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arrhythmic TMS
Description: TMS will be administered arrhythmically. In this intervention, the inter-pulse intervals are randomized between delta and theta durations for each trial, ensuring the same total number of pulses but without rhythmic consistency
Study: NCT06261086

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: evaluate serum levels pyroptosis-related indicators (GASDM-D, IL 1β & IL-18)
Description: 2 ml blood will be collected from all participants (patients and controls) by aseptic venipuncture into plain tubes. Then the samples will be allowed to coagulate during 10-20 minutes. Serum will be obtained by centrifugation at speed of 2000-3000 cycle/min for 20 minutes. Then we collect the supernatant which immediately be frozen at -80°C until analyzed to determine serum levels of pyroptosis-related indicators (GASDM-D, IL 1β \& IL-18). Serum concentration will be assessed by a commercially available double antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: evaluate serum levels pyroptosis-related indicators (GASDM-D, IL 1β & IL-18)
Description: 2 ml blood will be collected from all participants (patients and controls) by aseptic venipuncture into plain tubes. Then the samples will be allowed to coagulate during 10-20 minutes. Serum will be obtained by centrifugation at speed of 2000-3000 cycle/min for 20 minutes. Then we collect the supernatant which immediately be frozen at -80°C until analyzed to determine serum levels of pyroptosis-related indicators (GASDM-D, IL 1β \& IL-18). Serum concentration will be assessed by a commercially available double antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit
Study: NCT05006638

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipid Emulsion, Intravenous
Description: Lipid emulsion is a mixture of soybean oil, egg phospholipids, glycerine, and is available in 10%, 20%, and 30% strengths. It has been used for decades as parenteral nutrition and for caloric supplementation and essential fatty acid deficiency. It has also been used as a carrier for lipid soluble medications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: a drug used as an antidote for some types of pesticides

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atropine
Description: a drug used as an antidote for some types of pesticides

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toxogonin
Description: a drug used as an antidote for some types of pesticides

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Toxogonin
Description: a drug used as an antidote for some types of pesticides

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate Powder and ondansetron
Description: standard of care for treatment of aluminuim phosphide is provided for patients poisoned with aluminuim phosphide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Bicarbonate Powder and ondansetron
Description: standard of care for treatment of aluminuim phosphide is provided for patients poisoned with aluminuim phosphide
Study: NCT06038643

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational behavioural intervention and daily activities monitoring
Description: Social motivation manipulation, self-transcendence daily messaging, and daily activities monitoring through accelerometry. Participants in this arm will have a study partner who receives daily feedback on the main participant's daily step count.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Daily activities monitored through accelerometry.
Study: NCT05830396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol Hydrochloride
Description: Patients will either receive ambroxol or placebo. ambroxol will be given intially in a dosage of 600mg/day. After 1 week, this will be increased to 1200mg/day. After 2 weeks the maximum dosage of 1800mg/day will be given. In total, ambroxol will be administered for 48 weeks. This is followed by a 12 week washout period, after wich the final outcomes will be measured (week 60).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will either receive ambroxol or placebo. ambroxol will be given intially in a dosage of 600mg/day. After 1 week, this will be increased to 1200mg/day. After 2 weeks the maximum dosage of 1800mg/day will be given. In total, ambroxol will be administered for 48 weeks. This is followed by a 12 week washout period, after wich the final outcomes will be measured (week 60).
Study: NCT06418802

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: STN-DBS surgery
Description: bilateral subthalamic nucleus deep brain stimulation surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: STN-DBS surgery
Description: bilateral subthalamic nucleus deep brain stimulation surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pulse width
Description: a short pulse width (30s)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulse width
Description: a short pulse width (30s)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: frequency
Description: frequency parameters of STN-DBS (60,100, and 130HZ)
Study: NCT05205057

Intervention type: OTHER
Intervention: Saliva
Description: Unstimulated whole saliva is collected

Intervention type: OTHER
Intervention: Saliva
Description: Unstimulated whole saliva is collected
Study: NCT06450756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples arm
Description: The Couples Arm aims to improve family planning (FP) utilization in pastoralist communities, addressing significant disparities in contraceptive use and unmet FP needs between pastoralist and agrarian communities in Ethiopia. Pastoralist areas face challenges such as low contraceptive usage, high unmet FP needs, and elevated rates of maternal and child morbidity and mortality. In 2016, only 9.1% of women in pastoralist areas used contraceptives, compared to a 41% prevalence rate in 2019 for the general population in Ethiopia. Reasons for non-use of contraceptives include lack of knowledge, unwillingness, negative perceptions, desire for many children due to child mortality concerns, and male dominance in FP decision-making. The study hypothesizes that engaging men and educating women about FP could enhance FP utilization, increase male involvement in family planning, and empower women.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Male arm
Description: This arm focused on promoting male involvement in family planning (FP) through comprehensive health education and video messages. Husbands were encouraged to become supportive partners and share FP information with their wives. Separate education sessions were held for men, recognizing their greater exposure to social activities and information in pastoralist contexts. Pastoralist wives typically rely on their husbands for information due to limited social access. Women in pastoral communities have significant informal power in family decisions, influenced by factors such as age, husband's status, sons' ages, eloquence, and wisdom. Reproductive health discussions are primarily between husband and wife. Education aimed to improve modern contraceptive use, overcoming common barriers like husband objection and religious influence on decision-making.
Study: NCT06071403

Intervention type: OTHER
Intervention: (enteral feeding volume/ total fluid volume)*100%
Description: (enteral feeding volume/ total fluid volume)\*100%. Total fluid volume is defined as enteral feeding volume + parenteral fluid volume + other fluid volume

Intervention type: OTHER
Intervention: (enteral feeding volume/ total fluid volume)*100%
Description: (enteral feeding volume/ total fluid volume)\*100%. Total fluid volume is defined as enteral feeding volume + parenteral fluid volume + other fluid volume

Intervention type: OTHER
Intervention: (enteral feeding volume/ total fluid volume)*100%
Description: (enteral feeding volume/ total fluid volume)\*100%. Total fluid volume is defined as enteral feeding volume + parenteral fluid volume + other fluid volume
Study: NCT04985890

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-421
Description: 10mg/kg weekly intravenous infusion to substitute for for antiretroviral therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UB-421+chidamide
Description: 10 mg/kg UB-421 weekly intravenous infusion to substitute for antiretroviral therapy, and combined with oral 10 mg chidamide twice a week for 8 weeks. Chidamide taken on the one day and three days after the administration of UB-421.
Study: NCT05003713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125236
Description: CORT125236 Lipid Capsule Formulation 10-60 mg for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125236
Description: CORT125236 Lipid Capsule Formulation 10-60 mg for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125236
Description: CORT125236 Lipid Capsule Formulation 10-60 mg for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching CORT125236
Description: Placebo matching CORT125236 Lipid Capsule Formulation 10-60 mg for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching CORT125236
Description: Placebo matching CORT125236 Lipid Capsule Formulation 10-60 mg for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone tablet 25 mg (20 mg + 5 mg tablets) for oral administration